Edison Investment Research Comments On Endocyte

Edison Investment Research provided color on Endocyte

in a research investment summary published today. In the report, Edison Investment Research states, "Endocyte now trading below its cash value and offers a very strong investment case, even on the worst-case scenario that EC145 does not reach the market before the read-out of PROCEED and/or another study in, say, 2015. The recent sell-off therefore offers a geared play on this outcome." Shares of Endocyte were trading at $3.21 at the time of posting, down 3.90% from Wednesday's market close.